Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656536 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT03656536 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 167 participants.
The verdict
NCT03656536, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Pemigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03656536
The ClinicalTrials.gov registry entry for NCT03656536 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT03656536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03656536 about?
NCT03656536 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma". The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
What is the current status of trial NCT03656536?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2019-06-03. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT03656536?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Pemigatinib (DRUG).
Who is sponsoring clinical trial NCT03656536?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.